Physician profile
Harsh Duphare
NPI 1598775611
$4,248.68
in general payments reported to CMS, 2019-2025
28 companies · $540 in 2025
The $540 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $282 · 2021: $1,793 · 2022: $273 · 2023: $356 · 2024: $738 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,633.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $1,075.25 | 2019-2024 | Hanarostent Esophagus Tts(Ccc), Single Use Aspiration Needle Na-U200h, Evis Exera Lll Colonovideoscope |
| Boston Scientific Corporation | $969.46 | 2020-2025 | Exalt Model D, Axios |
| Abbvie INC. | $779.31 | 2019-2025 | Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $211.61 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $171.39 | 2025 | Tremfya |
| Lumendi LLC | $142.00 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.69 | 2019-2022 | |
| Medtronic, INC. | $103.44 | 2024 | Endoflip |
| Nestle Healthcare Nutrition INC. | $97.43 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $83.07 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $78.07 | 2021-2022 | |
| Apollo Endosurgery US INC | $60.78 | 2020 | |
| Braintree Laboratories, INC. | $44.68 | 2020-2022 | |
| Pentax of America, INC. | $40.32 | 2020 | |
| Alnylam Pharmaceuticals INC. | $28.91 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $27.72 | 2019-2021 | |
| Ambu INC. | $24.97 | 2020-2021 | |
| Cook Medical LLC | $23.83 | 2020 | |
| Madrigal Pharmaceuticals | $22.89 | 2025 | Rezdiffra |
| Biohaven Pharmaceutical Holding Company LTD. | $22.27 | 2022 | |
| Genzyme Corporation | $20.93 | 2025 | |
| Celgene Corporation | $18.17 | 2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $18.13 | 2021 | |
| Aimmune Therapeutics, INC. | $16.56 | 2025 | Zenpep |
| Echosens North America, INC. | $16.13 | 2022 | |
| Allergan, INC. | $15.32 | 2019 | |
| Pfizer INC. | $12.50 | 2019 | |
| Merit Medical Systems INC | $9.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsh Duphare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.